Bitcoin Group SE
F:ADE

Watchlist Manager
Bitcoin Group SE Logo
Bitcoin Group SE
F:ADE
Watchlist
Price: 27.5 EUR 1.78% Market Closed
Market Cap: €137.5m

Bitcoin Group SE
Investor Relations

Bitcoin Group SE is a German holding company centered on cryptocurrency trading. Its main business is tied to bitcoin.de, an online marketplace where private and institutional customers can buy and sell digital assets, especially Bitcoin and other major cryptocurrencies. Through its banking and platform operations, it also helps with custody and settlement around those trades. The company makes money mainly by charging fees on transactions and related crypto services. Its customers are people and firms that want a regulated way to trade or hold cryptocurrencies without dealing directly with another trader or a self-custody wallet. In practice, it sits between buyers, sellers, and the banking system, making crypto trading easier to access. What makes Bitcoin Group SE different is that it is not a general tech company or a broad financial group. It is a focused crypto infrastructure business with a marketplace, banking link, and custody functions built around digital assets. That gives it a role in the value chain as a trusted on-ramp and trading venue for cryptocurrency users in Germany and nearby markets.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2014
Call Date
Nov 11, 2014
AI Summary
Q2 2014

Strong growth: Management said first-half revenue rose 25%, with underlying growth of 23% after adjusting for currency and the partial-year impact of recent acquisitions.

Key drivers: TheraSphere and EKOS were highlighted as performing well, while Varithena’s U.S. controlled launch was described as on track and supported by positive physician feedback.

Outlook: The company said it remains on track to finish the year around the top end of guidance, with Varithena still expected to contribute only single-digit millions this year.

Margins and cash: Contribution margin was lower because of launch and expansion investments, but management said cash generation remained strong, with closing cash at $78 million.

Strategic progress: The company expanded its direct sales footprint in Europe, gained approval for DC Bead in China, and settled the CroFab litigation, removing a source of uncertainty.

Analyst focus: Questions centered on Varithena reimbursement, European Beads distribution, SG&A investment needs, tax benefits, and the long-term outlook for Zytiga royalties.

Key Financials
Revenue growth
25%
Contribution growth
20%
Profit before tax
15%
Cash
$78 million
Underlying revenue growth
23%
Interventional medicine revenue
$51.8 million
Interventional medicine contribution
$8.8 million
Varithena sales
single-digit million dollars
EKOS growth
28%
TheraSphere growth
25%
Specialty pharmaceuticals revenue growth
24%
Zytiga annual sales
around $2 billion
Licensing gross margin
around 50%
Bioclon litigation cost
about £4 million
Tax rate
around 26%
Other Earnings Calls
2014

Management

Mr. Marco Bodewein
CEO & Member of Management Board
No Bio Available
Mr. Per Hlawatschek
Member of Management Board & Chief Information Officer
No Bio Available
Mr. Michael Nowak
Member of Management Board
No Bio Available

Contacts

Address
NORDRHEIN-WESTFALEN
Herford
Luisenstrasse 4
Contacts
+4952216943520
bitcoingroup.com